Phase 2Active, not recruiting
GRK-Biased Activation Via β2-Adrenergic Receptors in Human Skeletal Muscle (GAIN)
G Protein-Coupled Receptor Kinase (GRK)-Biased Signaling Via β2-Adrenergic Receptors and Downstream Activation and Its Role for Protein Synthesis-Regulating Kinases, Function and Receptor Desensitization in Human Skeletal Muscle
- Sponsor
- Morten Hostrup, PhD (Academic or other)
- Enrolment
- 13 enrolled
- Conditions
- Overweight and Obesity
- Interventions
- ATR-258
- Ages
- adults
- Registry
- NCT07421024
Full record on ClinicalTrials.gov
From the registry
This longitudinal mechanistic physiological study examines biased β2-adrenergic receptor (β2-AR) signaling in human skeletal muscle, with emphasis on G protein-coupled receptor kinase (GRK)-mediated pathways. Participants will receive daily oral dosing of the GRK-selective long-acting β2-agonist ATR-258 for 8 weeks. Muscle biopsies and physiological measurements will quantify GRK-, cAMP/PKA-, and β-arrestin-related up- and downstream signaling, fiber-type specificity, and potential receptor desensitization with repeated stimulation along with functional read-outs, tissue distribution, cardiovascular response and tolerability.
Primary outcomes
- Intensity of β2-AR downstream signaling pathways (e.g. GRK, cAMP/PKA, β-arrestin, rpS6) in type I and type II muscle fibers
History
Primary completion expected
Last registry update
Registered
Started